Impact of the microbial derived short chain fatty acid propionate on host susceptibility to bacterial and fungal infections in vivo.

Détails

Ressource 1Télécharger: srep37944.pdf (2396.11 [Ko])
Etat: Serval
Version: Final published version
ID Serval
serval:BIB_CB627C7BE2E8
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Impact of the microbial derived short chain fatty acid propionate on host susceptibility to bacterial and fungal infections in vivo.
Périodique
Scientific reports
Auteur(s)
Ciarlo E., Heinonen T., Herderschee J., Fenwick C., Mombelli M., Le Roy D., Roger T.
ISSN
2045-2322 (Electronic)
ISSN-L
2045-2322
Statut éditorial
Publié
Date de publication
29/11/2016
Peer-reviewed
Oui
Volume
6
Pages
37944
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Résumé
Short chain fatty acids (SCFAs) produced by intestinal microbes mediate anti-inflammatory effects, but whether they impact on antimicrobial host defenses remains largely unknown. This is of particular concern in light of the attractiveness of developing SCFA-mediated therapies and considering that SCFAs work as inhibitors of histone deacetylases which are known to interfere with host defenses. Here we show that propionate, one of the main SCFAs, dampens the response of innate immune cells to microbial stimulation, inhibiting cytokine and NO production by mouse or human monocytes/macrophages, splenocytes, whole blood and, less efficiently, dendritic cells. In proof of concept studies, propionate neither improved nor worsened morbidity and mortality parameters in models of endotoxemia and infections induced by gram-negative bacteria (Escherichia coli, Klebsiella pneumoniae), gram-positive bacteria (Staphylococcus aureus, Streptococcus pneumoniae) and Candida albicans. Moreover, propionate did not impair the efficacy of passive immunization and natural immunization. Therefore, propionate has no significant impact on host susceptibility to infections and the establishment of protective anti-bacterial responses. These data support the safety of propionate-based therapies, either via direct supplementation or via the diet/microbiota, to treat non-infectious inflammation-related disorders, without increasing the risk of infection.
Mots-clé
Animals, Bacteria/drug effects, Bacteria/immunology, Bacterial Infections/drug therapy, Bacterial Infections/immunology, Bacterial Infections/microbiology, Fatty Acids, Volatile/pharmacology, Female, Fungi/drug effects, Fungi/immunology, Immunity, Innate/drug effects, Immunity, Innate/immunology, Inflammation/drug therapy, Inflammation/immunology, Inflammation/microbiology, Mice, Mice, Inbred BALB C, Mycoses/drug therapy, Mycoses/immunology, Mycoses/microbiology, Propionates/pharmacology
Pubmed
Web of science
Open Access
Oui
Création de la notice
06/12/2016 19:20
Dernière modification de la notice
09/05/2019 1:17
Données d'usage